Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer

Margaret M Kozak; Rie von Eyben; Jonathan Pai; Stephen R Vossler; Maneesha Limaye; Priya Jayachandran; Eric M Anderson; Jenny L Shaffer; Teri Longacre; Reetesh K Pai; Albert C Koong; Daniel T Chang

doi:10.1136/jclinpath-2014-202660

Article info

Original article

Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer

Authors

Margaret M Kozak Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Rie von Eyben Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Jonathan Pai Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Stephen R Vossler Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Maneesha Limaye Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Priya Jayachandran Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Eric M Anderson Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Jenny L Shaffer Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Teri Longacre Department of Pathology, Stanford University, Stanford, California, USA PubMed articles Google scholar articles
Reetesh K Pai Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA PubMed articles Google scholar articles
Albert C Koong Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles
Daniel T Chang Department of Radiation Oncology, Stanford Cancer Institute, Stanford, California, USA PubMed articles Google scholar articles

Correspondence to Dr Daniel T Chang, Department of Radiation Oncology, Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305-5847, USA; dtchang{at}stanford.edu

View Full Text

Citation

Kozak MM, von Eyben R, Pai J, et al

Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer

Journal of Clinical Pathology 2015;68:341-345.

Publication history

Received September 17, 2014
Revised December 2, 2014
Accepted January 18, 2015
First published February 13, 2015.

Online issue publication

October 25, 2017

Article Versions

Previous version (25 October 2017).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Article Versions

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password